|2.||Premature Birth (Birth, Premature)
|5.||Gestational Diabetes (Gestational Diabetes Mellitus)
|1.||Hillier, Sharon L: 23 articles (04/2015 - 10/2002)|
|2.||Sobel, Jack D: 13 articles (07/2015 - 07/2002)|
|3.||Reid, Gregor: 12 articles (01/2015 - 05/2006)|
|4.||Meyn, Leslie A: 10 articles (01/2015 - 03/2003)|
|5.||Temmerman, Marleen: 10 articles (01/2012 - 10/2002)|
|6.||Cauci, Sabina: 9 articles (02/2011 - 05/2002)|
|7.||Nyirjesy, Paul: 8 articles (04/2015 - 11/2004)|
|8.||Klebanoff, Mark A: 8 articles (11/2014 - 06/2003)|
|9.||Guaschino, Secondo: 8 articles (02/2013 - 05/2002)|
|10.||Verstraelen, Hans: 8 articles (01/2012 - 04/2004)|
|1.||Metronidazole (Metric)FDA LinkGeneric
07/01/2000 - "Most patients with odor had bacterial vaginosis and had an improvement in odor with topical metronidazole. "
04/01/1999 - "The most cost-effective treatment for bacterial vaginosis was generic metronidazole. "
07/01/1990 - "Metronidazole (500 mg twice daily for 7 days) continues to be highly efficacious in the treatment of bacterial vaginosis. "
12/01/2008 - "Intravaginally applied metronidazole is as effective as orally applied in the treatment of bacterial vaginosis, but exhibits significantly less side effects."
03/10/1991 - "Mobiluncus associated bacterial vaginosis can be treated successfully with 500 mg of metronidazole three times a day for seven days."
|2.||Clindamycin (Cleocin)FDA LinkGeneric
08/01/1995 - "Of the 80 patients who were recorded "success" or "improved" at visit 2, 20 (25%) were reported to have a "recurrence" of BV at Visit 3. The meta-analysis on those who were evaluable at Visit 2 and 3 also showed that clindamycin cream 2% was an effective treatment for bacterial vaginosis, and the differences between the clindamycin group and the placebo group were statistically significant. "
11/01/1994 - "Clindamycin eradicated and/or decreased counts of major bacterial vaginosis-associated microflora such as Gardnerella, gram-negative and gram-positive anaerobes, and Mycoplasma hominis; this was correlated with cure in 22 of 24 (92%) women. "
08/01/1995 - "We conclude that a 3 day course of clindamycin 2% cream is an effective, and well tolerated treatment for bacterial vaginosis."
11/01/1994 - "Microbial (and clinical) results support use of clindamycin as effective treatment of bacterial vaginosis."
11/01/1993 - "Intravaginal clindamycin 2% cream appears to be an effective and safe treatment of symptomatic bacterial vaginosis in nonpregnant women."
|3.||Vaginal Creams, Foams, and Jellies (Vaginal Tablet)IBA
06/01/2005 - "We evaluated the efficacy of a mucoadhesive vaginal gel (MVG, Miphil) with acidic-buffering properties in bacterial vaginosis (BV). "
01/01/2009 - "The purpose of this study was to determine the effectiveness of Lactobacillus-containing vaginal tablets in the treatment of bacterial vaginosis (BV) and in the restoration of a healthy vaginal flora. "
04/01/1994 - "Within this study, women with bacterial vaginosis (16 to 27 week' gestation) were treated with 2% clinadmycin vaginal cream or placebo. "
11/01/2014 - "Effectiveness of the two microorganisms Lactobacillus fermentum LF15 and Lactobacillus plantarum LP01, formulated in slow-release vaginal tablets, in women affected by bacterial vaginosis: a pilot study."
06/30/2011 - "plantarum [FV9]), whose effectiveness in treating bacterial vaginosis in the form of vaginal tablets has been reported recently, prevented sperm lipid peroxidation that was induced in vitro by a ferrous ion promoter, thus preserving sperm motility and viability. "
02/20/1991 - "Although there were no statistically significant differences between the two groups with respect to clinical effect and tolerance, the results do show that, for the treatment of bacterial vaginosis, a single dose of tinidazole represents a clinically effective and well-tolerated therapy that is minimally stressful for the patient and is particularly suitable for prescription by the practicing physician."
08/01/2007 - "Both tinidazole regimens studied provided effective treatment for bacterial vaginosis. "
02/01/2009 - "Improved cure of bacterial vaginosis with single dose of tinidazole (2 g), Lactobacillus rhamnosus GR-1, and Lactobacillus reuteri RC-14: a randomized, double-blind, placebo-controlled trial."
10/01/1993 - "A randomized double-blind trial of tinidazole treatment of the sexual partners of females with bacterial vaginosis."
09/01/1983 - "Oral tinidazole, 500 mg twice daily for 5 days, was compared to triple sulfonamide cream inserted into the vagina twice daily for 7 days for the treatment of nonspecific vaginitis in a placebo-controlled, double-blind trial. "
|5.||Erythromycin (Erycette)FDA LinkGeneric
07/01/1996 - "Reduced incidence of preterm delivery with metronidazole and erythromycin in women with bacterial vaginosis."
12/28/1995 - "Reduced incidence of preterm delivery with metronidazole and erythromycin in women with bacterial vaginosis."
09/01/1998 - "Two trials with use of metronidazole (alone or with erythromycin) showed a reduction in preterm delivery in women who were at a high risk of preterm delivery and had bacterial vaginosis at screening. "
12/28/1995 - "Treatment with metronidazole and erythromycin reduced rates of premature delivery in women with bacterial vaginosis and an increased risk for preterm delivery."
12/28/1995 - "Of the 358 women who did not have bacterial vaginosis when initially examined, 22 percent of those assigned to metronidazole and erythromycin and 25 percent of those assigned to placebo delivered prematurely (P = 0.55). "
|6.||Ascorbic Acid (Vitamin C)FDA LinkGeneric
01/01/2015 - "The effectiveness of intravaginal vitamin C versus placebo for the treatment of bacterial vaginosis: a systematic review protocol."
03/01/2015 - "(I-A) 5. Current evidence of the efficacy of alternative therapies for bacterial vaginosis (probiotics, vitamin C) is limited. "
08/01/2013 - "Efficacy of vitamin C vaginal tablets as prophylaxis for recurrent bacterial vaginosis: a randomised, double-blind, placebo-controlled clinical trial."
01/01/2011 - "Efficacy of vitamin C vaginal tablets in the treatment of bacterial vaginosis: a randomised, double blind, placebo controlled clinical trial."
08/01/2013 - "The study showed that regular use of 250 mg ascorbic acid vaginal tablets on 6 days per month for 6 months after successful treatment of bacterial vaginosis halves the risk of recurrence from 32.4% to 16.2% (P = 0.024)."
01/01/2013 - "[Efficacy of combined 5-nitroimidazole and probiotic therapy of bacterial vaginosis: randomized open trial]."
01/01/2013 - "The application of Gynophilus after conventional 5-nitroimidazole treatment for bacterial vaginosis increased the clinical and microbiological efficacy of the therapy by 25% - 30%. "
08/12/2008 - "[Efficacy of 5-nitroimidazole derivatives in treatment of bacterial vaginosis]."
08/12/2008 - "To evaluate the efficacy and adverse effects of 5-nitroimidazole derivatives in treatment of bacterial vaginosis (BV). "
04/01/1996 - "In summary, available evidence suggests that secnidazole is as efficacious as other 5-nitroimidazole drugs in the treatment of protozoal infections and bacterial vaginosis. "
08/01/2000 - "Vaginal fetal fibronectin was quantitatively determined in a prospective cohort study of 13,360 women being evaluated for participation in the National Institute of Child Health and Human Development Maternal-Fetal Medicine Unit treatment trials for bacterial vaginosis and Trichomonas vaginalis. "
10/01/2015 - "All women had risk factors for PTB: (1) positive fetal fibronectin (n = 146), (2) bacterial vaginosis (BV) and a prior PTB (n = 43), or (3) BV and a prepregnancy weight < 50 kg (n = 54). "
07/01/2010 - "The predictors studied included maternal age, parity, birthplace (as a proxy for ethnic origin), pre-pregnancy body mass index, height, smoking, bacterial vaginosis and vaginal fetal fibronectin (FFN) concentration. "
04/01/2010 - "We prospectively collected demographic and health status data, data on pre-pregnancy vaginal douching, vaginal smears for bacterial vaginosis as defined by Nugent's criteria, fetal fibronectin at 26 weeks of pregnancy, and placental pathology at delivery. "
12/01/2005 - "The other infectious markers tested were: bacterial vaginosis and fetal fibronectin in cervical secretions; serum CRP and white blood cell count. "
03/01/2005 - "To determine whether bacterial vaginosis could be cured with a single 1-g oral dose of secnidazole. "
03/01/2005 - "This clinical study showed that a single 1-g oral dose of secnidazole is effective to cure bacterial vaginosis associated with G. "
05/01/2010 - "In vitro activity of secnidazole against Atopobium vaginae, an anaerobic pathogen involved in bacterial vaginosis."
03/01/2005 - "Low-dose secnidazole in the treatment of bacterial vaginosis."
01/08/2009 - "Secnidazole (alpha,2-dimethyl-5-nitro-1H-imidazole-1-ethanol) is an antimicrobical drug, and it is particularly effective in the treatment of amebiasis, giardiasis, trichomoniasis, and bacterial vaginosis. "
|10.||clindamycin-2-phosphate (Clindets)FDA LinkGeneric
07/01/2010 - "To develop more effective treatment for bacterial vaginosis, bioadhesive film formulations of clindamycin phosphate (CL) for vaginal delivery were studied. "
07/01/1990 - "Blinded intravaginal clindamycin phosphate treatment cured bacterial vaginosis in 93.5% (43 of 46) of patients 4-7 days after therapy, compared with 25.0% (four of 16) of patients receiving placebo (P less than .001). "
06/01/1995 - "In recent clinical studies, clindamycin phosphate cream administered intravaginally has been shown to be efficacious in the treatment of bacterial vaginosis (BV). "
01/01/2000 - "To asses the efficiency of the 2% clindamycin phosphate creme given in 3 and 7 daily courses officially designer for the treatment of bacterial vaginosis (BV). "
07/01/1990 - "Bacterial vaginosis: treatment with topical intravaginal clindamycin phosphate."
10/01/2004 - "This study was undertaken to evaluate antimicrobial susceptibility of vaginal anaerobic bacteria before and after treatment of bacterial vaginosis. "
04/01/1998 - "Included in this study, which spanned the period from January 1988 to June 1996, were all patients who were referred by their gynecologists for continuing vulvovaginal symptoms after treatment for bacterial vaginosis. "
01/01/1997 - "The cure rate after treatment of bacterial vaginosis (BV) differs in various investigations, but most studies report a cure rate of 70% after 1 month. "
04/01/2015 - "However, the changes of vaginal flora after treatment were only examined by Nugent score in that clinical trial, While the vaginal microbiota of rhesus macaques is characterized by anaerobic, Gram-negative bacteria, few lactobacilli, and pH levels above 4.6, similar to the microbiota of patients with bacterial vaginosis. "
01/01/2015 - "The biofilm formation was captured in fresh wet-mount microscopic samples from asymptomatic patients after treatment for recurrent bacterial vaginitis. "
11/01/2007 - "When we excluded women with intermediate flora, consistent condom use was even more strongly protective against bacterial vaginosis (0.37 [0.20-0.70]). "
11/01/2007 - "Previous studies have been inconsistent with regard to whether condom use is associated with bacterial vaginosis. "
01/01/2013 - "Consistent condom use increases the colonization of Lactobacillus crispatus in the vagina and may protect against both bacterial vaginosis (BV) and human immunodeficiency virus (HIV)."
04/01/2009 - "Effect of consistent condom use on 6-month prevalence of bacterial vaginosis varies by baseline BV status."
11/01/2007 - "Consistent condom use was associated with a decrease in the risk for bacterial vaginosis and associated vaginal microflora."
07/01/2008 - "Safe and effective long-term vaginal administration of Lactobacillus rhamnosus appears to be a useful complementary approach in the management of bacterial vaginosis."
09/01/2010 - "Long-term vaginal administration of Lactobacillus rhamnosus as a complementary approach to management of bacterial vaginosis."
01/01/2009 - "The dominance of lactobacilli in healthy vaginal microbiota and its depletion in bacterial vaginosis (BV) has given rise to the concept of oral or vaginal instillation of probiotic Lactobacillus strains for the management of this condition. "
01/01/2009 - "The data indicate that intravaginal administration of exogenous selected strains of lactobacilli can restore a normal vaginal microbiota and be used in treating bacterial vaginosis."
09/01/2010 - "In summary, five days of vaginal administration of LN strains after conventional treatment of bacterial vaginosis and/or vulvovaginal candidiasis lead to vaginal colonization, somewhat fewer recurrences and less malodorous discharge."
|4.||Contraception (Birth Control)
07/01/2009 - "Hormonal contraception and risk of bacterial vaginosis diagnosis in an observational study of women attending STD clinics in Baltimore, MD."
01/01/2013 - "To examine the association between hormonal contraception (HC) and bacterial vaginosis (BV) by systematic review and meta-analysis. "
01/01/2013 - "Hormonal contraception is associated with a reduced risk of bacterial vaginosis: a systematic review and meta-analysis."
07/01/2009 - "The protective effect of hormonal contraception may offer a potential intervention against bacterial vaginosis (BV). "
05/15/2005 - "Genital tract shedding of herpes simplex virus type 2 in women: effects of hormonal contraception, bacterial vaginosis, and vaginal group B Streptococcus colonization."
11/01/2015 - "Pessaries are important options for women with pelvic floor disorders, but many pessary users experience bacterial vaginosis (BV). "
11/01/2015 - "The effect of hydroxyquinoline-based gel on pessary-associated bacterial vaginosis: a multicenter randomized controlled trial."
01/01/2000 - "Bacterial vaginosis (BV) was noted in 32% of pessary users, versus 10% of controls. "
01/01/2000 - "Bacterial vaginosis increases in pessary users."
12/01/1990 - "Metronidazole pessaries are effective in the treatment of bacterial vaginosis."